Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.63 |
| ▸ | ERBB2 | P04626 | 11/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5630815 | 1.00 | EGFR (0.63) | EGFRERBB2CCNA2CDK2CCNA1 | |
| SCHEMBL5629507 | 1.00 | EGFR (0.63) | EGFRERBB2CCNA2CDK2CCNA1 | |
| SCHEMBL5629802 | 0.93 | EGFR (0.54) | EGFRERBB2CCNA2CDK2CCNA1 | |
| SCHEMBL5629813 | 0.91 | EGFR (0.65) | EGFRERBB2CCNA2CDK2CCNA1 | |
| SCHEMBL5629580 | 0.91 | EGFR (0.65) | EGFRERBB2CCNA2CDK2CCNA1 | |
| SCHEMBL5631466 | 0.90 | EGFR (0.68) | EGFRERBB2CCNA2CDK2CCNA1 | |
| SCHEMBL5630741 | 0.90 | EGFR (0.68) | EGFRERBB2CCNA2CDK2CCNA1 | |
| SCHEMBL5629204 | 0.90 | EGFR (0.72) | EGFRERBB2CCNA2CDK2CCNA1 | |
| SCHEMBL5629158 | 0.90 | EGFR (0.71) | EGFRERBB2MKNK1 | |
| SCHEMBL5632273 | 0.89 | EGFR (0.66) | EGFRERBB2CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238701-B2 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-20060293322-A1 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-12-28 | — | — | US | disclosed |
| EP-1651652-B1 | SUBSTITUTED TETRAHYDROBENZOTHIENOPYRIMIDINAMINE COMPOUNDS USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORP (US) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293322-A1 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | MKI67, PCNA, MYC | EGFR 1499/4885ERBB2 692/4885CCNA2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.